New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on: December 22,2023

New therapeutic strategy for chemotherapy resistance in ovarian cancer

byThe Wistar InstituteDr. Rugang Zhang. Credit: The Wistar InstituteA study from The Wistar Institute demonstrated that NAMPT, an enzyme critical for NAD+ biosynthesis, mediates selection of ste

Updated on:December 22,2023

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was

Updated on: January 04,2024

Inhibition of prmt5 by repurposing market drugs: A fresh therapeutic pathway for cancer treatment

by TranSpreadDevelopment of AlphaLISA HTS screen to identify specific PRMT5 inhibitors. (A) Principle of AlphaLISA technique adapted to HTS. Biotinylated histone H4 (a well-known PRMT5 substrate) was

Updated on:January 04,2024

Tiny surgical robots could transform detection and treatment of cancers

byUniversity of LeedsRobotic platform for peripheral lung tumor intervention based on magnetic tentacles. Credit: STORM Lab, University of LeedsA tiny robot which can travel deep into the lungs

Updated on: January 08,2024

Tiny surgical robots could transform detection and treatment of cancers

byUniversity of LeedsRobotic platform for peripheral lung tumor intervention based on magnetic tentacles. Credit: STORM Lab, University of LeedsA tiny robot which can travel deep into the lungs

Updated on:January 08,2024

Uptake of HIV prevention medication doubles with mix of digital health interventions, study finds

by University of California, Los AngelesCredit: Pixabay/CC0 Public DomainA UCLA Health-led study found a combination of interventions of one-on-one telehealth coaching, peer support forums, and a

Updated on: May 16,2024

Uptake of HIV prevention medication doubles with mix of digital health interventions, study finds

by University of California, Los AngelesCredit: Pixabay/CC0 Public DomainA UCLA Health-led study found a combination of interventions of one-on-one telehealth coaching, peer support forums, and a

Updated on:May 16,2024

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on: December 26,2023

Revealing one of the mechanisms by which thyroid cancer becomes resistant to lenvatinib-a

by Shinshu UniversityThe EGFR-mediated pathway, which is not targeted by lenvatinib, is activated for survival in thyroid cancer cells under the potent inhibition of the VEGFR and FGFR families by len

Updated on:December 26,2023

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on: January 08,2024

Guideline updated for initial management of advanced prostate cancer

by Elana GotkineFor patients with noncastrate advanced prostate cancer, docetaxel, abiraterone, enzalutamide, apalutamide, or darolutamide are each recommended as standards of care with androgen depri

Updated on:January 08,2024

Fat fuels aggressive brain cancers

byCardiff UniversityGliobastoma (astrocytoma) WHO grade IV—MRI coronal view, post contrast. 15 year old boy. Credit: Christaras A/ Wikipedia.Fat is powering tumour growth in brain cancer, finds

Updated on: December 18,2023

Fat fuels aggressive brain cancers

byCardiff UniversityGliobastoma (astrocytoma) WHO grade IV—MRI coronal view, post contrast. 15 year old boy. Credit: Christaras A/ Wikipedia.Fat is powering tumour growth in brain cancer, finds

Updated on:December 18,2023

Cancer patients who don't respond to immunotherapy may lack crucial immune cells

byWashington University School of MedicineCD5+ DC frequency was reduced in tumor-affected lymph nodes, and their presence correlated with greater patient survival in multiple tumors. CD5+D

Updated on: December 20,2023

Cancer patients who don't respond to immunotherapy may lack crucial immune cells

byWashington University School of MedicineCD5+ DC frequency was reduced in tumor-affected lymph nodes, and their presence correlated with greater patient survival in multiple tumors. CD5+D

Updated on:December 20,2023

Discovery of drug candidate to potentially tackle ER-positive breast cancer

byMonash UniversityCredit:Cell Chemical Biology(2023). DOI: 10.1016/j.chembiol.2023.07.005An international team of researchers, led by Pfizer in collaboration with Monash University

Updated on: December 30,2023

Discovery of drug candidate to potentially tackle ER-positive breast cancer

byMonash UniversityCredit:Cell Chemical Biology(2023). DOI: 10.1016/j.chembiol.2023.07.005An international team of researchers, led by Pfizer in collaboration with Monash University

Updated on:December 30,2023

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on: July 11,2024

3D genome features point to possible therapeutic target for aggressive and deadly pediatric brain tumors

by Fabienne Landry,McGill University Health CentreCredit:Cell(2024). DOI: 10.1016/j.cell.2024.06.023Posterior fossa group A (PFA) ependymoma are rare, treatment-resistant pediatric t

Updated on:July 11,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on: April 28,2024

FDA approves Abecma for relapsed, refractory multiple myeloma

by Lori SolomonThe U.S. Food and Drug Administration has approved Abecma (idecabtagene vicleucel) as a personalized CAR T-cell therapy for triple-class exposed relapsed or refractory multiple myeloma.

Updated on:April 28,2024

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th

Updated on: January 05,2024

Blood-based biomarker may redefine future treatment for advanced melanoma

byElsevierCirculating tumor DNA (ctDNA) correlates with radiology disease assessment and patient outcome. For patient A, biomarkers in their blood decreased over time and the radiology showed th

Updated on:January 05,2024